

Description

The present invention relates to humanized antibodies specific for the protofibrillar form of β -amyloid peptide. The present invention also relates to the therapeutic, diagnostic and/or preventive use of these antibodies, in particular associated with the induction and with the progression of neurodegenerative disorders and/or with diseases associated with the deposition of amyloid plaques, and notably Alzheimer's disease.

Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects a high proportion of the older population. This disease is characterized clinically by memory loss and a decline in cognitive functions, and neuropathologically by the presence, in the brain, of intracellular neurofibrillar deposits and of extracellular deposits of the β -amyloid peptide (A- β) forming amyloid plaques. (Yanker et al. Nature Med. Vol. 2 No. 8 (1996)). As well as these signs, there are many other abnormal changes including a deterioration of the immune and inflammatory systems as well as a deterioration of mitochondrial function, which can lead to an increase in oxidative stress, activation of the mechanisms of apoptosis and ultimately to cell death.

Amyloid plaques are predominantly composed of A- β peptides with 40 or 42 residues, which are generated during the proteolytic process of the β -amyloid peptide precursor (APP) protein. The extracellular deposits of A- β peptides represent the invariable early characteristic feature of all forms of AD, including the familial forms (FAD). FADs appear relatively early (between 40 and 60 years) and are due to mutations in the gene of APP in 5% of cases of FAD (> 20 families) with six single or double missense mutations; in the gene of presenilin 1 (PS 1) in 50 to 70% of cases of FAD (> 200 families) with more than 80 different mutations identified to date; and in the gene of presenilin 2 (PS 2) in fewer cases of FAD with 2 missense mutations described in 8 families. Mutations in these

three genes have been shown to induce changes in the proteolysis of APP, which lead to overproduction of A- β and to the early appearance of the pathology and of symptoms that are similar to those of the sporadic forms of AD.

5

The neuronal toxicity of the amyloid plaques might reside in the high molecular weight fibrils that are formed by aggregation of soluble A- β peptides in fibrillar forms that are soluble initially (also called protofibrillar form) and
10 are then converted to insoluble forms incorporated in the amyloid plaques. In fact, it was shown in vitro that the soluble A- β peptide aggregates progressively to a fibrillar form (i.e. which can be labelled with agents such as Congo Red or thioflavin S which recognize the beta-sheet tertiary
15 structures of the peptides/proteins), of high molecular weight (>200 kDa) but still soluble. Because this form is soluble, it is often called the protofibrillar form, whereas the fibrils result from even greater aggregation, leading to loss of solubility. The protofibrillar transitional forms are
20 generally regarded as the precursors of the amyloid fibres and might be responsible for the cellular dysfunction and the neuronal loss in Alzheimer's disease and in other diseases associated with the aggregation of proteins.

25 It has been shown that the senile amyloid plaques (i.e. aggregated, also called mature plaques) are correlated with the cognitive status of Alzheimer's patients in contrast to the diffuse deposits of A- β peptide which are also widely present in unaffected patients. (Duyckaerts et al., Neurobiol.
30 Aging 1997; 18: 33-42 and Jellinger et al., 1998; 54:77-95). By targeting these senile amyloid plaques in particular, it is therefore possible to treat Alzheimer's disease more specifically and effectively.

35 A great many treatments have been tried for preventing the formation of the A- β peptides, for example inhibitors of the proteolytic process of APP.

Immunotherapeutic strategies such as the administration of anti-A- β antibody (to reduce the amyloid deposits) or immunization with antigens of the A- β peptides (to promote a humoral response) have been tested in order to reduce the size and density of the plaques.

For example, a method of treatment against Alzheimer's disease has been described (US 7 179 463), consisting of administering an antibody directed against a protofibril presenting an Arctic mutation in the region coding for the A- β peptide.

No example of antibody has really been described. Moreover, no comparison of the affinity of the antibodies for the peptides as a function of the molecular weight of these peptides has been performed. Other patents (US 6 761 888 and US 6 750 324) have referred to antibodies recognizing various epitopes along the amino acid sequence of the peptide A- β_{42} . An international application (WO2007/108756) has been filed concerning antibodies specific for the protofibrils but the antibodies described recognize both the high molecular weight A- β peptides and the medium-weight oligomers. Furthermore, there is no mention of the affinity of the antibodies for the mature plaques relative to their affinity for the diffuse plaques.

Schupf et al. (PNAS, 2008, vol. 105, No. 37, pp 14052-14057) describes the generation of a murine antibody (13C3) by immunization with the fibrillar form of the AB42 protein. The antibody 13C3 is specific for the protofibrillar form of the AB42 peptide and does not react with the low-molecular-weight fractions.

Despite the current development of knowledge concerning Alzheimer's disease, there is still a need for compositions and methods of treatment and/or prevention of this pathology limiting the secondary effects to the maximum extent. Antibodies such as described in the present application, humanized and specific for the protofibrillar form of the A- β peptides, aim to solve this problem. Permitting recognition of

the senile amyloid plaques but not the diffuse plaques, the antibodies according to the invention recognize the pathological plaques much more effectively than antibodies recognizing all forms of Abeta, which will largely be attached to the diffuse deposits or attached to the soluble forms of monomeric or low-molecular-weight A- β peptide.

Moreover, the fact that only the protofibrillar forms of the A- β peptides are recognized and not the protofibrillar forms of other proteins not linked to Alzheimer's disease avoids useless binding that may reduce the concentration of antibodies that are effective against the disease.

The murine antibody that has been humanized will be called antibody 13C3 throughout the present application.

The sequences that can code for or constitute the humanized antibodies described in the present application are shown in Table 2.

The present invention is defined by the claims.

The present application describes a humanized antibody that binds specifically to the protofibrillar form of the A- β peptide, i.e. a high molecular weight peptide.

In a more advantageous embodiment, the antibody binds to the A- β peptide having a molecular weight greater than 200, 300, 400 or 500 kDa.

It is also stated that the antibody binds to the A- β peptides aggregated into senile plaques and not to the diffuse deposits of A- β peptides.

In an advantageous embodiment, the antibody binds specifically to the protofibrillar form of the A- β peptide but not to the other proteins of amyloid structure (for example IAPP, Islet Amyloid Polypeptide).

The present application also describes a humanized antibody having reduced effector functions, making it possible to limit adverse effects such as the development of microhaemorrhages and vasogenic oedemas.

In an advantageous embodiment, the antibody no longer possesses effector functions.

In an even more advantageous embodiment, the antibody is an immunoglobulin G 4 whose Fc domain has undergone mutations reducing the production of half-molecules.

In an even more advantageous embodiment, the antibody is an immunoglobulin G 4 whose Fc domain has undergone mutations reducing the effector activity.

The present application describes a humanized antibody comprising at least one CDR encoded by a nucleotide sequence having a sequence identical to one of the sequences SEQ ID NO: 9, 11, 13, 15, 17 and 19, or by sequences differing respectively by 1, 2, 3, 4 or 5 nucleotides from these sequences.

The present application also describes a humanized antibody comprising at least one CDR having a sequence identical to one of the sequences SEQ ID NO: 10, 12, 14, 16, 18 and 20.

In another embodiment, the antibody described herein comprises at least one CDR whose sequence differs by one to two amino acids relative to one of the sequences SEQ ID NO: 10, 12, 14, 16, 18, 20 and 32, inasmuch as the antibody maintains its binding specificity.

In an advantageous embodiment, the antibody comprises the CDRs encoded by the nucleotide sequences SEQ ID NO: 9, 11, 13, 15, 17 and 19, or by sequences differing respectively by 1, 2, 3, 4 or 5 nucleotides from these sequences.

In another advantageous embodiment, the antibody comprises the CDRs of sequence SEQ ID NO: 10, 12, 14, 16, 18 and 20.

5 The antibody can also comprise the CDRs encoded by the nucleotide sequences SEQ ID NO: 9, 11, 13, 31, 17 and 19 or by sequences differing respectively by 1, 2, 3, 4 or 5 nucleotides from these sequences.

10 In an advantageous embodiment, the antibody comprises the CDRs of sequence SEQ ID NO: 10, 12, 14, 32, 18 and 20.

The present application describes the humanized antibody comprising the CDRs encoded by the nucleotide sequences SEQ ID
15 NO: 9, 11, 29, 31, 17 and 19 or by sequences differing respectively by 1, 2, 3, 4 or 5 nucleotides from these sequences.

The application also describes a humanized antibody comprising
20 the CDRs of sequence SEQ ID NO: 10, 12, 30, 32, 18 and 20.

In an advantageous embodiment, the antibody described herein comprises a variable part of its heavy chain (VH) encoded by a sequence having at least 80%, 85%, 90%, 95% or 99% identity
25 with the sequence SEQ ID NO: 5 or the sequence SEQ ID NO 27.

In an advantageous embodiment, the antibody described herein comprises a variable part of its heavy chain (VH) comprising a sequence having at least 80%, 85%, 90%, 95% or 99% identity
30 with the sequence SEQ ID NO: 6 or the sequence SEQ ID NO 28.

In an advantageous embodiment, the antibody described herein comprises a variable part of its light chain (VL) encoded by a sequence having at least 80%, 85%, 90%, 95% or 99% identity
35 with the sequence SEQ ID NO: 7 or the sequence SEQ ID NO 23.

In an advantageous embodiment, the antibody described herein comprises a variable part of its light chain (VL) comprising a

sequence having at least 80%, 85%, 90%, 95% or 99% identity with the sequence SEQ ID NO: 8 or the sequence SEQ ID NO 24.

5 In an even more advantageous embodiment, the antibody comprises a heavy chain comprising a variable part (VH) encoded by one of the nucleotide sequences SEQ ID NO 5 and SEQ ID NO 27.

10 In an even more advantageous embodiment, the antibody comprises a heavy chain comprising a variable part (VH) of polypeptide sequence SEQ ID NO 6 or SEQ ID NO 28.

15 In another embodiment, the antibody comprises a light chain comprising a variable part (VL) encoded by one of the nucleotide sequences SEQ ID NO 7 and SEQ ID NO 23.

20 In another embodiment, the antibody comprises a light chain comprising a variable part (VL) of polypeptide sequence SEQ ID NO 8 or SEQ ID NO 24.

In an advantageous embodiment, the antibody comprises the sequences encoded by the nucleotide sequences SEQ ID NO: 5 and 7.

25 In an advantageous embodiment, the antibody comprises the polypeptide sequences SEQ ID NO: 6 and 8.

In another embodiment, the antibody comprises the sequences encoded by the nucleotide sequences SEQ ID NO: 5 and 23.

30 In another embodiment, the antibody comprises the polypeptide sequences SEQ ID NO: 6 and 24.

35 In another embodiment, the antibody comprises the sequences encoded by the nucleotide sequences SEQ ID NO: 27 and 23.

In another embodiment, the antibody comprises the polypeptide sequences SEQ ID NO: 28 and 24.

The present application also describes an antibody comprising a heavy chain encoded by a sequence having at least 80%, 85%, 90%, 95% or 99% identity with one of the nucleotide sequences SEQ ID NO 1 and SEQ ID NO 25.

The present application also describes an antibody comprising a heavy chain having at least 80%, 85%, 90%, 95% or 99% identity with the polypeptide sequence SEQ ID NO 2 or with the polypeptide sequence SEQ ID NO 26.

In an advantageous embodiment the antibody described herein comprises a light chain encoded by a sequence having at least 80%, 85%, 90%, 95% or 99% identity with one of the nucleotide sequences SEQ ID NO 3 and SEQ ID NO 21.

In another embodiment the antibody described herein comprises a light chain comprising a sequence having at least 80%, 85%, 90%, 95% or 99% identity with one of the polypeptide sequences SEQ ID NO 4 and SEQ ID NO 22.

The present application describes an antibody comprising the sequences encoded by the nucleotide sequences SEQ ID NO: 1 and 3.

The present application describes an antibody whose sequence comprises the polypeptide sequences SEQ ID NO: 2 and 4.

The present application describes an antibody comprising the sequences encoded by the nucleotide sequences SEQ ID NO: 1 and 21.

The present application describes an antibody whose sequence comprises the polypeptide sequences SEQ ID NO: 2 and 22.

The present application describes an antibody comprising the sequences encoded by the nucleotide sequences SEQ ID NO: 25 and 21.

The present application describes an antibody whose sequence comprises the polypeptide sequences SEQ ID NO: 26 and 22.

- 5 The present application describes a humanized anti-peptide A β antibody having an affinity for the protofibrillar form of peptide A β at least 100 times greater than its affinity for the other forms of this peptide.
- 10 The present application describes an antibody, characterized in that it induces a reduction of amyloid plaques.

The present application describes the use of a humanized anti-peptide A β antibody in the treatment of diseases associated
15 with neurodegenerative disorders, and in particular in the treatment of Alzheimer's disease.

The present application describes a pharmaceutical composition comprising a humanized anti-peptide A β antibody and
20 excipients.

The present application describes a method of treatment of Alzheimer's disease comprising the administration of a humanized anti-peptide-A β antibody to the patient.

25 The present application describes a cell or cells producing a humanized anti-peptide-A β antibody, as well as the method of production of this antibody comprising the culturing of these cells. Said cells are derived advantageously from one cell
30 line.

The present application describes a medicinal product comprising a humanized anti-peptide-A β antibody.

- 35 The present application describes a polynucleotide coding for a polypeptide having at least 80%, 85%, 90%, 95% or 99% identity with one of the sequences SEQ ID NO: 2, 4, 6, 8, 22, 24, 26 or 28.

The present application describes a polynucleotide with a sequence having at least 80%, 85%, 90%, 95% or 99% identity with one of the sequences SEQ ID NO: 1, 3, 5, 7, 21, 23, 25, or 27.

The present application describes a recombinant vector comprising a nucleic acid having one of the sequences SEQ ID NO 1, 3, 5, 7, 21, 23, 25, or 27, as well as a host cell comprising this vector.

Definitions

Specific binding is understood as a difference by a factor of at least about 10, 20, 30, 40, 50, or 100 between the strength of binding to one receptor relative to another, here between binding to the protofibrillar form of the A- β peptide and binding to the other forms of the peptide.

"Epitope" means the site of the antigen to which the antibody binds. If the antigen is a polymer, such as a protein or a polysaccharide, the epitope can be formed by contiguous or non-contiguous residues. Here the epitope is conformational, i.e. related to the three-dimensional structure of the protofibrillar A- β peptide.

"Protofibrillar form" means an oligomeric form of A- β peptides, soluble in vitro and which can be isolated as an entity of molecular weight greater than 200 kDa, 300 kDa, 400 kDa or 500 kDa and which can fix agents such as thioflavin-S or Congo Red.

"Senile plaque" means a plaque composed of an amyloid core (fixing thioflavin S or Congo Red) surrounded by dystrophic neurites and a reaction of glial cells. Senile plaques are found in particular in patients with Alzheimer's disease, in contrast to the diffuse amyloid deposits (which do not fix thioflavin S or Congo Red), which are far more numerous but

are not associated with the disease.

An antibody, also called immunoglobulin, is composed of two identical heavy chains ("CH") and two identical light chains ("CL"), which are joined by a disulphide bridge. Each chain contains a constant region and a variable region. Each variable region comprises three segments called "complementarity determining regions" ("CDRs") or "hypervariable regions", which are mainly responsible for binding to the epitope of an antigen.

The term "VH" refers to the variable regions of a heavy chain of immunoglobulin of an antibody, including the heavy chains of a fragment Fv, scFv, dsFv, Fab, Fab' or F(ab)'.

The term "VL" refers to the variable regions of a light chain of immunoglobulin of an antibody, including the light chains of a fragment Fv, scFv, dsFv, Fab, Fab' or F(ab)'.

"Antibody" also means any functional fragment of antibody: Fab (Fragment antigen binding), Fv, scFv (single chain Fv), Fc (Fragment, crystallizable). Preferably, these functional fragments will be fragments of type Fv, scFv, Fab, F(ab')₂, Fab', scFv-Fc, diabodies, multispecific antibodies (notably bispecific), synthetic polypeptides containing the sequences of one or more CDRs, which generally possess the same specificity of fixation as the humanized antibody from which they are derived. According to the present invention, fragments of antibodies of the invention can be obtained from the humanized antibodies by methods such as digestion by enzymes, such as pepsin or papain and/or by cleavage of the disulphide bridges by chemical reduction.

Nanobodies also come under this definition.

"CDR or CDRs" denotes the hypervariable regions of the heavy and light chains of the immunoglobulins as defined by Kabat et al. (Kabat et al., Sequences of proteins of immunological

interest, 5th Ed., U.S. Department of Health and Human Services, NIH, 1991, and later editions). There are 3 heavy-chain CDRs and 3 light-chain CDRs. The term CDR or CDRs is used here to denote, as applicable, one or more, or even all, of these regions that contain the majority of the amino acid residues responsible for the affine binding of the antibody for the antigen or the epitope that it recognizes. The most conserved regions of the variable domains are called FR regions or sequences, for "framework regions".

The present application describes humanized antibodies.

"Humanized antibody" means an antibody that contains mainly human immunoglobulin sequences. This term generally refers to a non-human immunoglobulin that has been modified by incorporating human sequences or residues found in human sequences.

In general, humanized antibodies comprise one or typically two variable domains in which all or part of the CDR regions correspond to parts derived from the non-human parent sequence and in which all or part of the FR regions are derived from a human immunoglobulin sequence. The humanized antibody can then comprise at least one portion of a constant region of immunoglobulin (Fc), in particular that of the selected reference human immunoglobulin.

We thus try to obtain an antibody that is the least immunogenic in a human. Thus it is possible that one or two amino acids of one or more CDRs are modified by an amino acid that is less immunogenic for the human host, without substantially reducing the binding specificity of the antibody to the A- β peptide of high molecular weight. Furthermore, the residues of the framework regions need not be human and it is possible that they are not modified, as they do not contribute to the immunogenic potential of the antibody.

Several methods of humanization are known by a person skilled

in the art for modifying a non-human parent antibody to an antibody that is less immunogenic in humans. Complete identity of the sequences with a human antibody is not essential. In fact complete sequence identity is not necessarily a
5 predictive indicator of reduced immunogenicity and modification of a limited number of residues can lead to humanized antibodies presenting a very attenuated immunogenic potential in humans (Molecular Immunology (2007) 44, 1986-1998).

10 Some methods are for example the inclusion of CDRs (grafting) (EPO 0 239 400; WO 91/09967; and U.S. Pat. Nos. 5,530,101 and 5,585,089), the resurfacing (EPO 0 592 106; EPO 0 519 596; Padlan, 1991, Molec Imm 28(4/5):489-498; Studnicka et al.,
15 1994, Prot Eng 7(6):805-814; and Roguska et al., 1994, PNAS 91:969-973) or chain mixing (U.S. Pat. No. 5,565,332).

The present application describes in particular humanized antibodies whose variable parts are modified according to the
20 technology explained in international patent application WO 2009/032661.

This technique notably uses dynamic molecular simulation based on three-dimensional models of antibodies, said models being
25 constructed by homology.

The present application also describes any form of antibody having diminished effector functions, such as immunoglobulins bearing mutations of the Fc domain reducing its affinity for
30 the receptors of the immune system or such as nanobodies.

"Effector functions" means any fixation of the Fc domain of the antibody to receptors or proteins inducing immune responses. Decreasing these effector functions makes it
35 possible to reduce adverse effects such as the induction of microhaemorrhages (Racke et al. J Neurosci 2005, 25:629).

Affinity can be measured by any technique known by a person

skilled in the art. It is advantageously measured by the Biostat Speed technique developed on the basis of the algorithms described by Ratkovsk DA and Reedy TJ (Biometrics, 1986, 42, 575-82).

5

In order to permit expression of heavy chains and/or light chains of the antibody according to the invention, the polynucleotides coding for said chains are inserted in expression vectors. These expression vectors can be plasmids, YACs, cosmids, retroviruses, episomes derived from EBV, and all the vectors that a person skilled in the art may judge to be suitable for expression of said chains.

These vectors can be used for transforming cells advantageously derived from one cell line. Said cell line is even more advantageously derived from a mammal.

It is advantageously the CHO line or a line derived from this line, or the HEK293 line or a line derived from this line.

20

The transformation of the cells can be carried out by any method known by a person skilled in the art for introducing polynucleotides into a host cell. Said method can be transformation by means of dextran, precipitation by calcium phosphate, transfection by means of polybrene, protoplast fusion, electroporation, encapsulation of the polynucleotides in liposomes, biolistic injection and direct micro-injection of DNA into the nucleus.

The antibody according to the invention can be included in pharmaceutical compositions with a view to administration by the topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous, intraocular or other routes. Preferably, the pharmaceutical compositions contain pharmaceutically acceptable vehicles for an injectable formulation. These can be in particular sterile, isotonic saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, etc., or mixtures of

35

said salts), or dry compositions, notably lyophilized, which, by adding sterilized water or physiological serum as appropriate, permit injectable solutes to be constituted.

5 As an example, a pharmaceutical composition comprises (1) a Dulbecco phosphate buffer (pH ~ 7.4), optionally containing 1 mg/ml to 25 mg/ml of human serum albumin, (2) 0.9% w/v of sodium chloride (NaCl), and (3) 5% (w/v) of dextrose. It can also comprise an antioxidant such as tryptamine and a
10 stabilizer such as Tween 20.

The pathologies in question can be any diseases associated with the deposition of amyloid plaques. In particular, the pathology in question is Alzheimer's disease.

15 The doses depend on the desired effect, the duration of the treatment and the route of administration used; they are generally between 5 mg and 1000 mg of antibody per day for an adult. Generally the doctor will determine the appropriate
20 dosage in relation to the stage of the disease, the patient's age and weight, or any other patient-related factor that has to be taken into account.

The present invention is illustrated, but is not limited, by
25 the examples given below.

Brief description of the drawings:

Fig. 1A: Map of the plasmid pXL4973 permitting expression of
30 the light chain LC1 of the antiAbeta antibody 13C3-VH1VL1.

Fig. 1B: Map of the plasmid pXL4979 permitting expression of the heavy chain HC1 of the antiAbeta antibody 13C3-VH1VL1.

35 **Fig. 2A and 2B:** Separation of the protofibrils and of the low-molecular-weight oligomers by gel filtration on Superdex 75 (at t=0 and at t=16h respectively).

Fig. 3: Determination of the molecular weight of the protofibrils.

Fig. 4A, 4B and 4C: Determination of the affinities of the humanized antibodies (antibodies LP09027 (4A), LP09026 (4B) and LP09028 (4C) respectively) for the protofibrils (mean value from 3 experiments $\pm$ sem).

Fig. 5: Specificity of the humanized antibody LP09027 with respect to fibrils of A β .

Fig. 6A and 6B: Specificity of the humanized antibody (LP09027) for the mature senile plaques respectively of the frontal cortex (6A) and of the hippocampus (6B) of a mouse. The arrows indicate the senile plaques.

EXAMPLES:

Example 1: Obtaining humanized antibodies

A murine antibody 13C3 was humanized.

This example describes the sequence and the production of the humanized anti-peptide A β antibody VH1VL1 (LP09027) by production by transient expression in the mammalian line HEK293 designated FreeStyle 293-F.

The cDNAs coding for the humanized variable chains VL1 and VH1 are fused with the cDNAs coding for the human constant regions Ckappa and IgG4 respectively. The sequence of the constant region IgG4 is that of the variant having the substitutions S241P and L248E in Kabat's nomenclature, for a significant reduction in the production of half-molecules (Angla et al., 1993, *Mol. Immunol.*, 30: 105-108) and the effector functions (WO 97/09351).

The nucleic acid sequences coding for CH1 (SEQ ID NO 1) and for CL1 (SEQ ID NO 3) were cloned independently in the

expression vector to generate the plasmids pXL4973 (Fig. 1A) and pXL4979 (Fig. 1B), respectively.

A batch of the antibody is produced by production by transient expression in the line FreeStyle 293-F (Invitrogen) after co-transfection of the plasmids pXL4973 and pXL4979 according to the protocol described by Invitrogen (catalogue reference K9000-01). This batch (LP09027) is then purified by affinity chromatography on a column of MabSelect gel (Amersham) according to the supplier's recommendations and then formulated in PBS buffer (reference Dulbecco 14190-094) and submitted to sterile filtration (0.2 μ m). Starting from 1 L of culture, 33 mg of antibody is obtained at a purity of 97% by SDS-PAGE in denaturing conditions and by steric exclusion chromatography. The mass obtained by SDS-PAGE in denaturing conditions and by LC/MS is in agreement with the primary amino acid sequence and the presence of an N-glycan on the Fc domain, namely a mass of 23969 Da for LC1 and 49650 Da for HC1 taking into account the N-glycan in the G0F form. The mass obtained by SDS-PAGE in non-denaturing conditions and by size exclusion chromatography is in agreement with the heterotetrameric structure of the antibody of 150 kDa (Fig. 4A).

According to the same method, batches of humanized antibodies LP09026 and LP09028 were produced starting from the nucleotide sequences SEQ ID NO 25 and SEQ ID NO 21 for LP09026 (Fig. 4B), and SEQ ID NO 1 and SEQ ID NO 21 for LP09028 (Fig. 4C).

Example 2: Preparation of protofibrils from peptide A β (1-42)

The protofibrils were prepared from the synthetic peptide A β (1-42) according to the method described by Johansson et al. (FEBS, 2006, 2618-2630). The lyophilized peptide (Anaspec reference 24224) is dissolved in 10 mM NaOH at a concentration of 100 μ M, then stirred for 1 min and incubated on ice for 10 min. The solution of peptide is then diluted in buffer of 100 mM sodium phosphate, 200 mM NaCl pH=7.4 to a concentration of 50 μ M, then stirred for 1 min. The preparation is incubated

overnight at 37°C for formation of protofibrils and then centrifuged at 17900g for 15 min at 16°C to remove the insoluble aggregates. To separate the protofibrils from the oligomeric forms of A β of low molecular weight, the supernatant is loaded on a Superdex 75 gel filtration column equilibrated in 50 mM ammonium acetate buffer pH=8.5. The fractions corresponding to the protofibrils and to the low-molecular-weight oligomers are collected and stored at 4°C. Fig. 2 shows a typical profile of separation of the protofibrils. The molecular weight of the protofibrils is determined by Superdex200 gel filtration using, as markers of molecular weight, the Biorad calibration kit (reference 150-1901). Fig. 3 shows that the molecular weight of the protofibrils is greater than 200 kDa.

Example 3: Specificity and affinity of the humanized antibodies with respect to the protofibrils

50 μ l of protofibrils and low-molecular-weight oligomers at a concentration of 1 μ g/ml in PBS (Gibco, reference 70011) are deposited in the wells of an ELISA plate (Nunc, reference 442404) and incubated overnight at 4°C. After removing the excess antigen, 200 μ l of buffer PBS + 5% milk powder (weight/volume) is deposited in each well to remove the non-specific adsorptions and incubated for 2h at room temperature. The wells are then washed 4 times with 300 μ l of buffer PBS Tween 0.02%. 50 μ l of a primary antibody solution (dilution of 3 in 3 in PBS Tween starting from a concentration of 100 μ g/ml for the oligomers and from 25 μ g/ml for the protofibrils) is added to each well and incubated for 1h at room temperature. The wells are washed 4 times with 300 μ l of buffer PBS Tween. The secondary anti-Fc human antibody coupled to peroxidase (Goat Anti Human IgG (Fc) peroxidase conjugated, Pierce, reference 31413) diluted to 1/10000 in buffer PBS Tween is added to each well and incubated for 1 h at room temperature. After 4 washings with 300 μ l of PBS Tween, 100 μ l of TMB (Interchim, reference UP664782) is added to each well and incubated for about 10 min, then the reaction is stopped with

a solution of 1M HCl (Interchim, reference UPS29590) and the plates are read at an OD measured at a wavelength of 450nm. The EC50 values are determined by BioStat Speed. The results obtained are presented in Table 1 and in Fig. 4 and show the very high specificity of the antibody for the protofibrils relative to the low-molecular-weight oligomers (factor of 184).

Table 1:

EC50 (µg/ml)	LMW	PF	LMW/PF
LP09026	41.4 ± 40.1	0.0587 ± 0.004	705.3
LP09027	14.7 ± 2.7	0.0798 ± 0.007	184.2
LP09028	21.8 ± 5.3	0.0892 ± 0.007	244.4

The lyophilized peptide Aβ1-42 (Anaspec reference 24224) is dissolved according to the supplier's recommendations: 40 µl of 1% NH4OH is added to 500 µg of Aβ1-42. After complete dissolution, 460 µl of PBS is added to obtain a concentration of 1 mg/ml. Aliquots of 10 µl are prepared and stored at -80°C.

50µl of a solution of peptide Aβ1-42 at a concentration of 1 µg/ml in carbonate buffer (NaHCO₃ 0.025 M (Acros Organics, reference 217120010), Na₂CO₃ 0.025 M (Acros Organics, reference 207810010), pH 9.7 is deposited in the wells of an ELISA plate and incubated overnight at room temperature. As previously, the wells are washed with buffer PBS Tween, incubated in the presence of buffer PBS + 5% milk powder (weight/volume) and washed with buffer PBS Tween. The humanized antibody at a concentration of 0.02 µg/ml is incubated for 1h at room temperature with a concentration range (starting from 1 µg/ml) of peptides Aβ1-28 (Bachem, reference H7865), Aβ1-16 (Anaspec, reference 24225), Aβ25-35 (Anaspec, reference 24227), low-molecular-weight oligomers or protofibrils prepared as described previously. The antibody/antigen mixture is then deposited in each well and the microtitration plate is incubated for 1h at room temperature. The free, uncomplexed

antibody is determined according to the same ELISA protocol as described previously. These competitive experiments show that only the protofibrils with a much higher affinity than the low-molecular-weight oligomers are capable of neutralizing the humanized antibody by preventing it from interacting with the peptide A β 1-42; none of the peptides is capable of neutralizing the antibody.

Example 4: Specificity of the humanized antibody LP09027 with respect to the fibrils of A β 1-42

The peptide A β 1-42 (Anaspec, 20276) is dissolved in 200 μ l of 10 mM NaOH to a concentration of 5 mg/ml. The peptide IAPP (Anaspec, 60804) is diluted in 200 μ l of 50% DMSO to a concentration of 5 mg/ml. 100 μ l of each preparation is diluted in 400 μ l of PBS 1.25X. The final concentration of the peptides is 1 mg/ml in 500 μ l. The samples are incubated for 72h at 37°C. After incubation, the samples are centrifuged at 17900g for 30 minutes at 4°C. The supernatant is removed and the pellet is washed 3 times with PBS 1X. After the last washing, the pellet of fibrils is taken up in 150 μ l of PBS. To check for the presence of fibrils of amyloid type, a thioflavin T fluorescence test (Anaspec, 88306) is carried out. 20 μ l of thioflavin T (20 μ M final), 10 μ l of the sample and 70 μ l of PBS 1X (final volume 100 μ l) are mixed in a well of a black plate (Corning, 3792). The thioflavin T is excited at 450 nm and, in the presence of a structure of amyloid type, emits fluorescence at 482 nm. 50 μ l of fibrils of A β 1-42 at 1 μ g/ml and IAPP at 0.5 μ g/ml are deposited in each well of a microtitration plate. The ELISA protocol is applied using serial dilutions of the humanized antibody starting from 10 μ g/ml. Fig. 5 shows that the humanized antibody LP09027 specifically recognizes the fibrils of A β 1-42 but not those of IAPP.

Example 5: Specificity of the humanized antibody LP09027 for the mature senile plaques but not for the diffuse plaques

The humanized antibody (LP09027) conjugated with digoxigenin (digoxigenin-3-O-methylcarbonyl- ϵ -aminocaproic acid-N-hydroxysuccinimide ester: Roche 11333054001; 11418165001) was used in immunohistochemistry (Ventana Robot) on brain sections from mice APP PS1 (Alzheimer model described by Schmitz C. et al., Am. J. Pathol, 2004, 164, 1495-1502) as well as human brain sections (cerebral cortex) derived from patients with Alzheimer's disease. The samples had been fixed in formol and embedded in paraffin beforehand.

The results obtained in the mouse (Figs. 6A and 6B) clearly show that the humanized antibody recognizes exclusively the dense, mature senile plaques, but not the diffuse deposits of peptide A β .

These data correlate with the properties of this antibody, which is specific for the protofibrillar Abeta form and so does not recognize the soluble, mono- or oligomeric forms of this peptide.

Table 2:

	Nucleotide sequences	Protein sequences
Antibody 1 VH1VL1		
VH ₁ + CH ₁	SEQ ID NO 1	SEQ ID NO 2
VL ₁ + CL ₁	SEQ ID NO 3	SEQ ID NO 4
VH ₁	SEQ ID NO 5	SEQ ID NO 6
VL ₁	SEQ ID NO 7	SEQ ID NO 8
CDR VH ₁	SEQ ID NO 9, 11, 13	SEQ ID NO 10, 12, 14
CDR VL ₁	SEQ ID NO 15, 17, 19	SEQ ID NO 16, 18, 20
Antibody 2 VH1 VL2		
VH ₁ + CH ₁	SEQ ID NO 1	SEQ ID NO 2
VL ₂ + CL ₂	SEQ ID NO 21	SEQ ID NO 22
VH ₁	SEQ ID NO 5	SEQ ID NO 6

VL ₂	SEQ ID NO 23	SEQ ID NO 24
CDR VH ₁	SEQ ID NO 9, 11, 13	SEQ ID NO 10, 12, 14
CDR VL ₂	SEQ ID NO 31, 17, 19	SEQ ID NO 32, 18, 20
Antibody 3 VH2 VL2		
VH ₂ + CH ₂	SEQ ID NO 25	SEQ ID NO 26
VL ₂ + CL ₂	SEQ ID NO 21	SEQ ID NO 22
VH ₂	SEQ ID NO 27	SEQ ID NO 28
VL ₂	SEQ ID NO 23	SEQ ID NO 24
CDR VH ₂	SEQ ID NO 9, 11, 29	SEQ ID NO 10, 12, 30
CDR VL ₂	SEQ ID NO 31, 17, 19	SEQ ID NO 32, 18, 20

SEQUENCE LISTING

<110> SANOFI-AVENTIS

<120> Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide

<130> FR2009-054

<160> 32

<170> PatentIn version 3.3

<210> 1

<211> 1326

<212> DNA

<213> Artificial

<220>

<223> Humanized sequence

<220>

<221> CDS

<222> (1)..(1326)

<400> 1

gag gtc cag ctg cag cag tct ggg cct gag gtg gtg aag cct ggg gtc	48
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Val	
1 5 10 15	
tca gtg aag att tcc tgc aag ggt tcc ggc tac aca ttc act gat tat	96
Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr	
20 25 30	
gct atg cac tgg gtg aag cag agt cct ggc aag agt ctg gag tgg att	144
Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile	
35 40 45	
gga gtt att agt act aag tat ggt aag aca aac tac aac ccc agc ttt	192
Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe	
50 55 60	
cag ggc cag gcc aca atg act gtt gac aaa tcc tcc agc aca gcc tat	240
Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr	
65 70 75 80	
atg gag ctt gcc agc ttg aag gcc tcc gat tct gcc atc tat tac tgt	288
Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys	
85 90 95	
gca aga ggg gac gat ggt tat tcc tgg ggt caa gga acc tca gtc acc	336
Ala Arg Gly Asp Asp Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr	
100 105 110	
gtc tcc agc gct tct acc aag ggc cct tcc gtg ttc cct ctg gcc cct	384
Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro	
115 120 125	
tgc tcc cgg tcc acc tcc gag tcc acc gcc gct ctg ggc tgc ctg gtg	432
Cys Ser Arg Ser Thr Ser Thr Ala Ala Leu Gly Cys Leu Val	
130 135 140	
aag gac tac ttc cct gag cct gtg acc gtg tcc tgg aac tct ggc gcc	480
Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala	

145	150	155	160	
ctg acc tcc ggc gtg cac acc ttc cct gcc gtg ctg cag tcc tcc ggc Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly	165	170	175	528
ctg tac tcc ctg tcc tcc gtg gtg acc gtg cct tcc tcc tcc ctg ggc Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly	180	185	190	576
acc aag acc tac acc tgt aac gtg gac cac aag cct tcc aac acc aag Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys	195	200	205	624
gtg gac aag cgg gtg gag tcc aag tac gcc cct cct tgc cct ccc tgc Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys	210	215	220	672
cct gcc cct gag ttc gag gcc gga cct agc gtg ttc ctg ttc cct cct Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro	225	230	235	720
aag cct aag gac acc ctg atg atc tcc cgg acc cct gag gtg acc tgt Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys	245	250	255	768
gtg gtg gtg gac gtg tcc cag gag gac cct gag gtc cag ttc aac tgg Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp	260	265	270	816
tac gtg gac gcc gtg gag gtg cac aac gcc aag acc aag cct cgg gag Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu	275	280	285	864
gag cag ttc aat tcc acc tac cgg gtg gtg tct gtg ctg acc gtg ctg Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu	290	295	300	912
cac cag gac tgg ctg aac gcc aaa gaa tac aag tgt aag gtc tcc aac His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn	305	310	315	960
aag gcc ctg ccc tcc tcc atc gag aaa acc atc tcc aag gcc aag gcc Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly	325	330	335	1008
cag cct agg gag cct cag gtg tac acc ctg cct cct agc cag gaa gag Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu	340	345	350	1056
atg acc aag aac cag gtg tcc ctg acc tgt ctg gtg aag ggc ttc tac Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr	355	360	365	1104
cct tcc gac atc gcc gtg gag tgg gag tcc aac gcc cag cct gag aac Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn	370	375	380	1152
aac tac aag acc acc cct cct ctg ctg gac tcc gac gcc tcc ttc ttc Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe	385	390	395	1200
ctg tac tcc agg ctg acc gtg gac aag tcc cgg tgg cag gag ggc aac Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn	405	410	415	1248
gtc ttt tcc tgc tcc gtg atg cac gag gcc ctg cac aac cac tac acc Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr	420	425	430	1296
cag aag tcc ctg tcc ctg tct ctg gcc tga Gln Lys Ser Leu Ser Leu Ser Leu Gly	435	440		1326

<210> 2

<211> 441

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 2

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Val
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe
50 55 60

Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys
85 90 95

Ala Arg Gly Asp Asp Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr
100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
115 120 125

Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val
130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly

180	185	190
Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys 195 200 205		
Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys 210 215 220		
Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240		
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 245 250 255		
Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp 260 265 270		
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 275 280 285		
Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 290 295 300		
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 305 310 315 320		
Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 325 330 335		
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu 340 345 350		
Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 355 360 365		
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 370 375 380		
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 385 390 395 400		
Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn 405 410 415		
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 420 425 430		
Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440		

<210> 3

<211> 660

<212> DNA

<213> Artificial

<220>

<223> Humanized sequence

<220>

< 221> CDS

< 222> (1)..(660)

<400> 3

```

gag atc gtg atg acc caa act cca ctc tcc ctg cct gtc agt ctt gga      48
Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1          5          10          15

gat aga gcc tcc atc tct tgc aga tct ggt cag agc ctt gtg cac agt      96
Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser
          20          25          30

aat gga aac acc tat ctg cat tgg tac ctg cag aag cca ggc cag tct     144
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
          35          40          45

cca aag ctc ctg atc tat aca gtt tcc aac cga ttt tct ggg gtc ccg     192
Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro
          50          55          60

gac agg ttc agt ggc agt gga tca ggg tca gat ttc aca ctc acc atc     240
Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile
65          70          75          80

agc aga gtg gag gct gag gat ctg gga gtt tat ttc tgc tct caa aat     288
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn
          85          90          95

aca ttt gtt cct tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa     336
Thr Phe Val Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
          100          105          110

cgt acg gtg gct gca cca tct gtc ttc atc ttc ccg cca tct gat gag     384
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
          115          120          125

cag ttg aaa tct gga act gcc tct gtt gtg tgc ctg ctg aat aac ttc     432
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
          130          135          140

tat ccc aga gag gcc aaa gta cag tgg aag gtg gat aac gcc ctc caa     480
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
          145          150          155          160

tcg ggt aac tcc cag gag agt gtc aca gag cag gac agc aag gac agc     528
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
          165          170          175

acc tac agc ctc agc agc acc ctg acg ctg agc aaa gca gac tac gag     576
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
          180          185          190

aaa cac aaa gtc tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg     624

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
          195          200          205

ccc gtc aca aag agc ttc aac agg gga gag tgt tga      660
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
          210          215

```

<210> 4

< 211> 219

< 212> PRT

< 213> Artificial

<220>

< 223> Synthetic Construct

<400> 4

Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser
20 25 30

Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn
85 90 95

Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 5

< 211> 345

< 212> DNA

< 213> Artificial

<220>

< 223> Humanized sequence

<220>

< 221> CDS

< 222> (1)..(345)

<400> 5

gag gtc cag ctg cag cag tct ggg cct gag gtg gtg aag cct ggg gtc	48
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Val	
1 5 10 15	
tca gtg aag att tcc tgc aag ggt tcc ggc tac aca ttc act gat tat	96
Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr	
20 25 30	
gct atg cac tgg gtg aag cag agt cct ggc aag agt ctg gag tgg att	144
Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile	
35 40 45	
gga gtt att agt act aag tat ggt aag aca aac tac aac ccc agc ttt	192
Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe	
50 55 60	
cag ggc cag gcc aca atg act gtt gac aaa tcc tcc agc aca gcc tat	240
Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr	
65 70 75 80	
atg gag ctt gcc agc ttg aag gcc tcc gat tct gcc atc tat tac tgt	288
Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys	
85 90 95	
gca aga ggg gac gat ggt tat tcc tgg ggt caa gga acc tca gtc acc	336
Ala Arg Gly Asp Asp Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr	
100 105 110	
gtc tcc agc	345
Val Ser Ser	
115	

<210> 6

< 211> 115

< 212> PRT

< 213> Artificial

<220>

< 223> Synthetic Construct

<400> 6

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Val
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe
50 55 60

Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys
85 90 95

Ala Arg Gly Asp Asp Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr
100 105 110

Val Ser Ser
115

<210> 7

<211> 339

<212> DNA

<213> Artificial

<220>

<223> Humanized sequence

<220>

<221> CDS

<222> (1)..(339)

<400> 7

gag atc gtg atg acc caa act cca ctc tcc ctg cct gtc agt ctt gga 48
Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

gat aga gcc tcc atc tct tgc aga tct ggt cag agc ctt gtg cac agt 96
Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser
20 25 30

aat gga aac acc tat ctg cat tgg tac ctg cag aag cca ggc cag tct 144
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

cca aag ctc ctg atc tat aca gtt tcc aac cga ttt tct ggg gtc ccg 192
Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

gac agg ttc agt ggc agt gga tca ggg tca gat ttc aca ctc acc atc 240
Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile

65		70		75		80	
agc aga gtg gag gct gag gat ctg gga gtt tat ttc tgc tct caa aat							288
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn							
	85			90		95	
aca ttt gtt cct tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa							336
Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys							
	100			105		110	
cgt							339
Arg							

<210> 8

<211> 113

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 8

Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly													
1		5				10						15	
Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser													
	20					25						30	
Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser													
	35					40						45	
Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro													
	50					55						60	
Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile													
65				70				75					80
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn													
	85							90					95
Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys													
	100							105					110

Arg

<210> 9

<211> 33

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(33)

<400> 9

```

tcc ggc tac aca ttc act gat tat gct atg cac
Ser Gly Tyr Thr Phe Thr Asp Tyr Ala Met His
1           5           10

```

33

<210> 10

<211> 11

<212> PRT

<213> Mus sp.

<400> 10

```

Ser Gly Tyr Thr Phe Thr Asp Tyr Ala Met His
1           5           10

```

<210> 11

<211> 30

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(30)

<400> 11

```

gtt att agt act aag tat ggt aag aca aac
Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn
1           5           10

```

30

<210> 12

<211> 10

<212> PRT

<213> Mus sp.

<400> 12

```

Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn
1           5           10

```

<210> 13

<211> 18

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(18)

<400> 13

ggg gac gat ggt tat tcc
 Gly Asp Asp Gly Tyr Ser
 1 5

18

<210> 14

<211> 6

<212> PRT

<213> Mus sp.

<400> 14

Gly Asp Asp Gly Tyr Ser
 1 5

<210> 15

<211> 48

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(48)

<400> 15

aga tct ggt cag agc ctt gtg cac agt aat gga aac acc tat ctg cat
 Arg Ser Gly Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His
 1 5 10 15

48

<210> 16

<211> 16

<212> PRT

<213> Mus sp.

<400> 16

Arg Ser Gly Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His
 1 5 10 15

<210> 17

<211> 24

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(24)

<400> 17

aca gtt tcc aac cga ttt tct ggg
 Thr Val Ser Asn Arg Phe Ser Gly
 1 5

24

<210> 18

<211> 8

<212> PRT

<213> Mus sp.

<400> 18

Thr	Val	Ser	Asn	Arg	Phe	Ser	Gly
1				5			

<210> 19

<211> 27

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(27)

<400> 19

tct	caa	aat	aca	ttt	gtt	cct	tg	acg
Ser	Gln	Asn	Thr	Phe	Val	Pro	Trp	Thr
1				5				

27

<210> 20

<211> 9

<212> PRT

<213> Mus sp.

<400> 20

Ser	Gln	Asn	Thr	Phe	Val	Pro	Trp	Thr
1				5				

<210> 21

<211> 660

<212> DNA

<213> Artificial

<220>

<223> Humanized sequence

<220>

<221> CDS

<222> (1)..(660)

<400> 21

gag atc gtg atg acc caa act cca ctc tcc ctg cct gtc agt ctt gga	48
Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	
1 5 10 15	
gat aga gcc tcc atc tct tgc aga tct ggt cag agc ctt gtg cac agt	96
Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser	
20 25 30	
aat acc aac acc tat ctg cat tgg tac ctg cag aag cca ggc cag tct	144
Asn Thr Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
cca aag ctc ctg atc tat aca gtt tcc aac cga ttt tct ggg gtc ccg	192
Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro	
50 55 60	
gac agg ttc agt ggc agt gga tca ggg tca gat ttc aca ctc acc atc	240
Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile	
65 70 75 80	
agc aga gtg gag gct gag gat ctg gga gtt tat ttc tgc tct caa aat	288
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn	
85 90 95	
aca ttt gtt cct tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa	336
Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys	
100 105 110	
cggt acg gtg gct gca cca tct gtc ttc atc ttc ccg cca tct gat gag	384
Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu	
115 120 125	
cag ttg aaa tct gga act gcc tct gtt gtg tgc ctg ctg aat aac ttc	432
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe	
130 135 140	
tat ccc aga gag gcc aaa gta cag tgg aag gtg gat aac gcc ctc caa	480
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln	
145 150 155 160	
tcg ggt aac tcc cag gag agt gtc aca gag cag gac agc aag gac agc	528
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser	
165 170 175	
acc tac agc ctc agc agc acc ctg acg ctg agc aaa gca gac tac gag	576
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu	
180 185 190	
aaa cac aaa gtc tac gcc tgc gaa gtc acc cat cag ggc ctg agc tcg	624
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser	
195 200 205	
ccc gtc aca aag agc ttc aac agg gga gag tgt tga	660
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys	
210 215	

<210> 22

<211> 219

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 22

Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser
20 25 30

Asn Thr Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn
85 90 95

Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

100

105

110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115 120 125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130 135 140

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
145 150 155 160

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
165 170 175

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
180 185 190

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
195 200 205

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 23

<211> 339

<212> DNA

<213> Artificial

<220>

<223> Humanized sequence

<220>

<221> CDS

<222> (1)..(339)

<400> 23

gag atc gtg atg acc caa act cca ctc tcc ctg cct gtc agt ctt gga	48
Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly	
1 5 10 15	
gat aga gcc tcc atc tct tgc aga tct ggt cag agc ctt gtg cac agt	96
Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser	
20 25 30	
aat acc aac acc tat ctg cat tgg tac ctg cag aag cca ggc cag tct	144
Asn Thr Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser	
35 40 45	
cca aag ctc ctg atc tat aca gtt tcc aac cga ttt tct ggg gtc ccg	192
Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro	
50 55 60	
gac agg ttc agt ggc agt gga tca ggg tca gat ttc aca ctc acc atc	240
Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile	
65 70 75 80	
agc aga gtg gag gct gag gat ctg gga gtt tat ttc tgc tct caa aat	288
Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn	
85 90 95	
aca ttt gtt cct tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa	336
Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys	
100 105 110	
cgt	339
Arg	

<210> 24

<211> 113

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 24

Glu Ile Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
 1 5 10 15

Asp Arg Ala Ser Ile Ser Cys Arg Ser Gly Gln Ser Leu Val His Ser
 20 25 30

Asn Thr Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Lys Leu Leu Ile Tyr Thr Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn
 85 90 95

Thr Phe Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105 110

Arg

<210> 25

<211> 1326

<212> DNA

<213> Artificial

<220>

<223> Humanized sequence

<220>

<221> CDS

<222> (1)..(1326)

<400> 25

gag gtc cag ctg cag cag tct ggg cct gag gtg gtg aag cct ggg gtc Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Val 1 5 10 15	48
tca gtg aag att tcc tgc aag ggt tcc ggc tac aca ttc act gat tat Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30	96
gct atg cac tgg gtg aag cag agt cct ggc aag agt ctg gag tgg att Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile 35 40 45	144
gga gtt att agt act aag tat ggt aag aca aac tac aac ccc agc ttt Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe 50 55 60	192
cag ggc cag gcc aca atg act gtt gac aaa tcc tcc agc aca gcc tat Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80	240
atg gag ctt gcc agc ttg aag gcc tcc gat tct gcc atc tat tac tgt Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys 85 90 95	288
gca aga ggg gac gag ggt tat tcc tgg ggt caa gga acc tca gtc acc Ala Arg Gly Asp Glu Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr 100 105 110	336
gtc tcc agc gct tct acc aag ggc cct tcc gtg ttc cct ctg gcc cct Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro 115 120 125	384
tgc tcc cgg tcc acc tcc gag tcc acc gcc gct ctg ggc tgc ctg gtg Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val 130 135 140	432
aag gac tac ttc cct gag cct gtg acc gtg tcc tgg aac tct ggc gcc Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 145 150 155 160	480
ctg acc tcc ggc gtg cac acc ttc cct gcc gtg ctg cag tcc tcc ggc Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly 165 170 175	528
ctg tac tcc ctg tcc tcc gtg gtg acc gtg cct tcc tcc tcc ctg ggc Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly 180 185 190	576
acc aag acc tac acc tgt aac gtg gac cac aag cct tcc aac acc aag Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys 195 200 205	624
gtg gac aag cgg gtg gag tcc aag tac ggc cct cct tgc cct ccc tgc Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys 210 215 220	672
cct gcc cct gag ttc gag ggc gga cct agc gtg ttc ctg ttc cct cct Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 225 230 235 240	720
aag cct aag gac acc ctg atg atc tcc cgg acc cct gag gtg acc tgt	768

Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	
				245					250						255	
gtg	gtg	gtg	gac	gtg	tcc	cag	gag	gac	cct	gag	gtc	cag	ttc	aac	tgg	816
Val	Val	Val	Asp	Val	Ser	Gln	Glu	Asp	Pro	Glu	Val	Gln	Phe	Asn	Trp	
			260					265					270			
tac	gtg	gac	ggc	gtg	gag	gtg	cac	aac	gcc	aag	acc	aag	cct	cgg	gag	864
Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	
		275					280					285				
gag	cag	ttc	aat	tcc	acc	tac	cgg	gtg	gtg	tct	gtg	ctg	acc	gtg	ctg	912
Glu	Gln	Phe	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	
		290					295				300					
cac	cag	gac	tgg	ctg	aac	ggc	aaa	gaa	tac	aag	tgt	aag	gtc	tcc	aac	960
His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	
305					310					315					320	
aag	ggc	ctg	ccc	tcc	tcc	atc	gag	aaa	acc	atc	tcc	aag	gcc	aag	ggc	1008
Lys	Gly	Leu	Pro	Ser	Ser	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	
				325					330					335		
cag	cct	agg	gag	cct	cag	gtg	tac	acc	ctg	cct	cct	agc	cag	gaa	gag	1056
Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Gln	Glu	Glu	
			340					345					350			
atg	acc	aag	aac	cag	gtg	tcc	ctg	acc	tgt	ctg	gtg	aag	ggc	ttc	tac	1104
Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	
		355					360					365				
cct	tcc	gac	atc	gcc	gtg	gag	tgg	gag	tcc	aac	ggc	cag	cct	gag	aac	1152
Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	
		370				375					380					
aac	tac	aag	acc	acc	cct	cct	gtg	ctg	gac	tcc	gac	ggc	tcc	ttc	ttc	1200
Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	
385					390					395					400	
ctg	tac	tcc	agg	ctg	acc	gtg	gac	aag	tcc	cgg	tgg	cag	gag	ggc	aac	1248
Leu	Tyr	Ser	Arg	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Glu	Gly	Asn	
				405					410					415		
gtc	ttt	tcc	tgc	tcc	gtg	atg	cac	gag	gcc	ctg	cac	aac	cac	tac	acc	1296
Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	
			420					425					430			
cag	aag	tcc	ctg	tcc	ctg	tct	ctg	ggc	tga							1326
Gln	Lys	Ser	Leu	Ser	Leu	Ser	Leu	Gly								
		435					440									

<210> 26

<211> 441

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 26

Glu	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Val	Val	Lys	Pro	Gly	Val
1				5					10					15	

Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30
 Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile
 35 40 45
 Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe
 50 55 60
 Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys
 85 90 95
 Ala Arg Gly Asp Glu Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr
 100 105 110
 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
 115 120 125
 Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val
 130 135 140
 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
 145 150 155 160
 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
 165 170 175
 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
 180 185 190
 Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys
 195 200 205
 Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys
 210 215 220
 Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 225 230 235 240
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 245 250 255
 Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp
 260 265 270

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
275 280 285

Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
290 295 300

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
305 310 315 320

Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
325 330 335

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu
340 345 350

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
355 360 365

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
370 375 380

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
385 390 395 400

Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn
405 410 415

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
420 425 430

Gln Lys Ser Leu Ser Leu Ser Leu Gly
435 440

<210> 27

<211> 345

<212> DNA

<213> Artificial

<220>

<223> Humanized sequence

<220>

<221> CDS

<222> (1)..(345)

<400> 27

gag gtc cag ctg cag cag tct ggg cct gag gtg gtg aag cct ggg gtc 48
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Val
1 5 10 15

tca gtg aag att tcc tgc aag ggt tcc ggc tac aca ttc act gat tat 96
Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

```

gct atg cac tgg gtg aag cag agt cct ggc aag agt ctg gag tgg att      144
Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile
      35              40              45

gga gtt att agt act aag tat ggt aag aca aac tac aac ccc agc ttt      192
Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe
      50              55              60

cag ggc cag gcc aca atg act gtt gac aaa tcc tcc agc aca gcc tat      240
Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
      65              70              75              80

atg gag ctt gcc agc ttg aag gcc tcc gat tct gcc atc tat tac tgt      288
Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys
      85              90              95

gca aga ggg gac gag ggt tat tcc tgg ggt caa gga acc tca gtc acc      336
Ala Arg Gly Asp Glu Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr
      100              105              110

gtc tcc agc
Val Ser Ser
      115

```

<210> 28

<211> 115

<212> PRT

<213> Artificial

<220>

<223> Synthetic Construct

<400> 28

```

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Val Val Lys Pro Gly Val
1              5              10              15

Ser Val Lys Ile Ser Cys Lys Gly Ser Gly Tyr Thr Phe Thr Asp Tyr
      20              25              30

Ala Met His Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp Ile
      35              40              45

Gly Val Ile Ser Thr Lys Tyr Gly Lys Thr Asn Tyr Asn Pro Ser Phe
      50              55              60

Gln Gly Gln Ala Thr Met Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
      65              70              75              80

Met Glu Leu Ala Ser Leu Lys Ala Ser Asp Ser Ala Ile Tyr Tyr Cys
      85              90              95

Ala Arg Gly Asp Glu Gly Tyr Ser Trp Gly Gln Gly Thr Ser Val Thr
      100              105              110

Val Ser Ser

```

115

<210> 29

<211> 18

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(18)

<400> 29

```

ggg gac gag ggt tat tcc
Gly Asp Glu Gly Tyr Ser
1           5

```

18

<210> 30

<211> 6

<212> PRT

<213> Mus sp.

<400> 30

```

Gly Asp Glu Gly Tyr Ser
1           5

```

<210> 31

<211> 48

<212> DNA

<213> Mus sp.

<220>

<221> CDS

<222> (1)..(48)

<400> 31

```

aga tct ggt cag agc ctt gtg cac agt aat acc aac acc tat ctg cat
Arg Ser Gly Gln Ser Leu Val His Ser Asn Thr Asn Thr Tyr Leu His
1           5           10           15

```

48

<210> 32

<211> 16

<212> PRT

<213> Mus sp.

<400> 32

```

Arg Ser Gly Gln Ser Leu Val His Ser Asn Thr Asn Thr Tyr Leu His
1           5           10           15

```

Patentkrav

1. Humaniseret antistof, som er specifikt for den protofibrillære form af A β -peptidet, kendetegnet ved, at:
- 5 - antistoffet har reducerede effektorfunktioner,
- den variable del af dets tunge kæde omfatter en sekvens, som udviser mindst 90 % identitet med sekvensen SEQ ID NO: 6 eller SEQ ID NO: 28,
- den variable del af dets lette kæde omfatter en sekvens, som
10 udviser mindst 90 % identitet med sekvensen SEQ ID NO: 8 eller SEQ ID NO: 24,
- antistoffet har en affinitet for den protofibrillære form af A β -peptidet, som er mindst 100 gange større end dets affinitet for de andre former af dette peptid, idet affiniteten er EC50
15 målt ved ELISA, og
- antistoffet binder sig til de A β -peptider, som er aggregeret i senile plaques, og ikke til de diffuse aflejringer af A β -peptider.
- 20 2. Antistof ifølge krav 1, kendetegnet ved, at antistoffet er et immunglobulin, som bærer mutationer i Fc-domænet, der reducerer dets affinitet for receptorerne i immunsystemet.
3. Antistof ifølge krav 1 eller 2, kendetegnet ved, at
25 antistoffet er et immunglobulin G4, hvis Fc-domæne har gennemgået mutationer, der reducerer effektoraktiviteten.
4. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det omfatter mindst én CDR, som
30 kodes for af en nukleotidsekvens, der har en sekvens, som er identisk med en af sekvenserne SEQ ID NO: 9, 11, 13, 15, 17 og 19, eller af sekvenser, som afviger med henholdsvis 1, 2, 3, 4 eller 5 nukleotider fra disse sekvenser.
- 35 5. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det omfatter mindst én CDR, der har en sekvens, som er identisk med en af sekvenserne SEQ ID NO: 10, 12, 14, 16, 18 og 20.

6. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det omfatter mindst én CDR, hvis sekvens afviger med en til to aminosyrer i forhold til en af sekvenserne SEQ ID NO: 10, 12, 14, 16, 18 og 20, idet antistoffet bevarer sin bindingsspecificitet.

7. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det omfatter de CDR, som kodes for af (i) nukleotidsekvenserne SEQ ID NO: 9, 11, 13, 15, 17 og 19, (ii) nukleotidsekvenserne SEQ ID NO: 9, 11, 13, 31, 17 og 19, (iii) nukleotidsekvenserne SEQ ID NO: 9, 11, 29, 31, 17 og 19, eller af sekvenser, som afviger med henholdsvis 1, 2, 3, 4 eller 5 nukleotider fra disse sekvenser.

8. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det omfatter de CDR, som har sekvensen SEQ ID NO: 10, 12, 14, 16, 18 og 20, de CDR, som har sekvensen SEQ ID NO: 10, 12, 14, 32, 18 og 20, eller de CDR, som har sekvensen SEQ ID NO: 10, 12, 30, 32, 18 og 20.

9. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at:

- den variable del af dets tunge kæde kodes for af en sekvens, som udviser mindst 80 % identitet med en af sekvenserne SEQ ID NO: 5 og SEQ ID NO: 27,

- den variable del af dets lette kæde kodes for af en sekvens, som udviser mindst 80 % identitet med en af sekvenserne SEQ ID NO: 7 og SEQ ID NO: 23,

- det omfatter en tung kæde, som kodes for af en sekvens, der udviser mindst 80 % identitet med en af nukleotidsekvenserne SEQ ID NO: 1 og SEQ ID NO: 25, og/eller en tung kæde, der udviser mindst 80 % identitet med en af polypeptidsekvenserne SEQ ID NO: 2 og SEQ ID NO: 26, og/eller

- det omfatter en let kæde, som kodes for af en sekvens, der udviser mindst 80 % identitet med en af nukleotidsekvenserne SEQ ID NO: 3 og SEQ ID NO: 21, og/eller en let kæde, der udviser mindst 80 % identitet med en af polypeptidsekvenserne

SEQ ID NO: 4 og SEQ ID NO: 22.

10. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at:

- 5 - det omfatter sekvenser, som kodes for af (i) nukleotidsekvenserne SEQ ID NO: 5 og 7, (ii) nukleotidsekvenserne SEQ ID NO: 5 og 23 eller (iii) nukleotidsekvenserne SEQ ID NO: 27 og 23, og/eller sekvenser, som kodes for af (i) nukleotidsekvenserne SEQ ID NO: 1 og 3,
10 (ii) nukleotidsekvenserne SEQ ID NO: 1 og 21 eller (iii) nukleotidsekvenserne SEQ ID NO: 25 og 21, og/eller
- dets sekvens omfatter polypeptidsekvenserne (i) SEQ ID NO: 6 og 8, (ii) SEQ ID NO: 6 og 24 eller (iii) SEQ ID NO: 28 og 24, og/eller polypeptidsekvenserne (i) SEQ ID NO: 2 og 4, (ii) SEQ
15 ID NO: 2 og 22 eller (iii) SEQ ID NO: 26 og 22.

11. Antistof ifølge et hvilket som helst af de foregående krav, kendetegnet ved, at det inducerer en reduktion af amyloid-plaques.

20

12. Antistof ifølge et hvilket som helst af kravene 1 til 11 til anvendelse ved behandling af sygdomme, som er forbundet med neurodegenerative forstyrrelser.

25 13. Antistof til anvendelse ifølge krav 12 ved behandling af Alzheimers sygdom.

14. Farmaceutisk sammensætning, som omfatter et antistof ifølge et hvilket som helst af kravene 1-11 og hjælpestoffer.

30

15. Celle, som fremstiller et antistof ifølge et hvilket som helst af kravene 1 til 11.

16. Fremgangsmåde til fremstilling af et antistof ifølge et
35 hvilket som helst af kravene 1 til 11, kendetegnet ved, at den omfatter dyrkning af celler ifølge krav 15.

17. Antistof ifølge et hvilket som helst af kravene 1 til 11

til anvendelse som lægemiddel.

18. Polynukleotid, som udtrykker antistoffet ifølge et hvilket som helst af kravene 1 til 11, kendetegnet ved, at
5 polynukleotidet koder for et polypeptid, der udviser mindst 90 % identitet med en af sekvenserne SEQ ID NO: 2, 4, 6, 8, 22, 24, 26 eller 28 eller har en sekvens, som udviser mindst 90 % identitet med en af sekvenserne SEQ ID NO: 1, 3, 5, 7, 21, 23, 25 eller 27.

10

19. Rekombinant vektor, som omfatter en nukleinsyre ifølge krav 18.

20. Værtscelle, som omfatter en vektor ifølge krav 19.